Kane Biotech Inc. announced new manufacturing partnership with Dow Development Laboratories, LLC ("DDL”) to scale up the process and, ultimately, manufacture materials under Good Manufacturing Practices (GMP) for a first-in-human proof of concept trial. Specifically, DDL will be responsible for manufacturing clinical batches of DispersinB® hydrogel to be used for a randomized study planned for 2022 on patients suffering from multiple chronic wound types to establish safety and efficacy.